Clovis Oncology - CLVS Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clovis Oncology in the last twelve months. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" CLVS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CLVS, but not buy additional shares or sell existing shares.
View CLVS analyst ratings or view top-rated stocks.

2 brokerages have issued 12-month price targets for Clovis Oncology's shares. Their CLVS share price forecasts range from $5.00 to $5.00. On average, they anticipate the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 6,150.0% from the stock's current price.
View analysts price targets for CLVS or view top-rated stocks among Wall Street analysts.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our CLVS earnings forecast.

Clovis Oncology (NASDAQ:CLVS) released its quarterly earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by $0.08. The biopharmaceutical company had revenue of $37.92 million for the quarter, compared to the consensus estimate of $38.73 million. During the same quarter in the prior year, the company earned ($0.89) EPS.

12 employees have rated Clovis Oncology Chief Executive Officer Patrick J. Mahaffy on Glassdoor.com. Patrick J. Mahaffy has an approval rating of 49% among the company's employees. This puts Patrick J. Mahaffy in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Clovis Oncology investors own include Gilead Sciences (GILD), Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Tesla (TSLA), Amarin (AMRN), Intercept Pharmaceuticals (ICPT), Netflix (NFLX) and Alibaba Group (BABA).

Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."

Clovis Oncology's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Cutler Group LLC CA (0.00%), Bank of Montreal Can (0.00%), Wolverine Asset Management LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Daniel W Muehl, Gillian C Ivers-Read, Lindsey Rolfe, Paul Edward Gross, Thomas C Harding and Thomas C Harding.
View institutional ownership trends.

One share of CLVS stock can currently be purchased for approximately $0.08.

Clovis Oncology (NASDAQ:CLVS) has a market capitalization of $11.60 million and generates $148.76 million in revenue each year. The biopharmaceutical company earns $-264,520,000.00 in net income (profit) each year or ($1.83) on an earnings per share basis.

Clovis Oncology's mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. The official website for the company is www.clovisoncology.com. The biopharmaceutical company can be reached via phone at 303-625-5000, via email at bburkart@clovisoncology.com, or via fax at 303-245-0360.